Centessa Pharmaceuticals plc announced new data from an additional 52-we weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia. The data were shared in a poster presentation at the American Society of Hematology (ASH) Annual Meeting on December 10, 2023. During treatment with SerpinPC all breakthrough bleeds were treated on-demand w ith usual clotting factor concentrate, without dose reduction and without limitation of number of infusions.

Data from Part 5 were presented at the ASH Annual Meeting in a poster titled: SerpinPC in persons with severe hemophilia (PwH): Updated results from a multi-center, multi-part, first-in-human study.